Showing 1 - 10 of 10
News, Post Reporters, Published on 19/11/2021
» Chulalongkorn University's Centre of Excellence in Vaccine Research and Development expects to register its mRNA Covid-19 vaccine, known as ChulaCov-19, in the middle of next year.
Post Reporters, Published on 18/11/2021
» Chulalongkorn University’s Centre of Excellence in Vaccine Research and Development expects to register its mRNA Covid-19 vaccine, known as ChulaCOV-19, mid-next year.
Business, Chatrudee Theparat, Published on 05/11/2021
» The cabinet on Thursday approved a combined 3.62 billion baht budget proposed by the National Economic and Social Development Council to finance R&D on two Covid-19 vaccine projects.
News, Post Reporters, Published on 28/08/2021
» Prime Minister Prayut Chan-o-cha has set a new target to prepare the country for a future with Covid-19, according to sources at Government House.
News, Post Reporters, Published on 20/08/2021
» Researchers behind domestic vaccine efforts need 3 billion baht in assistance each from the government to support their vaccine research and development projects so the jabs can be rolled out before April.
Oped, Postbag, Published on 19/08/2021
» Re: "Agro tycoon weighs in on post- Covid recovery", (BP, Aug 17).
News, Apinya Wipatayotin, Published on 17/08/2021
» The research team behind the development of a local mRNA Covid-19 vaccine on Monday asked the government to help finance the project and relax regulations so the jab can be deployed before April.
News, Post Reporters, Published on 15/06/2021
» Chulalongkorn University's mRNA Covid-19 vaccine, ChulaCov19, began its first round of human trials yesterday on 72 volunteer test subjects.
Life, Published on 15/06/2021
» As many countries are being devastated by shortages of Covid-19 vaccines, Chulalongkorn University is giving Thailand a new lease of life with its ChulaCov 19 vaccine, which began phase one of human clinical trials yesterday.
News, Apinya Wipatayotin, Published on 19/02/2021
» The mRNA ChulaCOV 19 vaccine which Thailand is developing will enter the first stage of human trials in May with hopes to produce a maximum of five million shots with its partner, vaccine manufacturer BioNet Asia, by the end of this year.